What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain”In the company’s words, NCT07326813 on ClinicalTrials.gov
- Tested for
- Plaque Psoriasis (2 trials), UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis, PsA (Psoriatic Arthritis), Psoriasis, Vitiligo, Non-Segmental Vitiligo (NSV), Active Systemic Lupus Erythematosus and 3 more
- Main trialPhase 3
- “This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points…”In the company’s words, NCT07326813 on ClinicalTrials.gov
Other drugs for Plaque Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
Coming up8
- 21 NovPhase 1 trial completes · ClinicalTrials.gov
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 12 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 15 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Aug 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 12 Jul 2027 | A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis | |
| Phase 3Recruiting | 28 Jul 2027 | Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis | |
| Phase 2Active, not recruiting | 30 Jul 2026 | A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Recruiting | 15 Aug 2027 | A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis | |
| Phase 2Recruiting | Aug 2027 | A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 2Recruiting | Nov 2027 | Study of D-2570 in Subjects With Non-Segmental Vitiligo | |
| Phase 2Recruiting | 31 Aug 2028 | A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) | |
| Phase 1Active, not recruiting | 31 Mar 2026 | Mass Balance Study of [14C] D-2570 | |
| Phase 1Active, not recruiting | 25 Jun 2026 | Healthy Volunteer Study | |
| Phase 1Recruiting | 31 Oct 2026 | A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function | |
| Phase 1Recruiting | 21 Nov 2026 | The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function. | |
| Phase 1Not yet recruiting | 31 Dec 2026 | A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults | |
| Phase 2Completed | 1 Nov 2024 | Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis | |
| Phase 1Completed | 23 Jun 2025 | Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026